Researchers have made a significant first step with newly engineered biomaterials for cell transplantation that could help lead to a possible cure for Type 1 diabetes, which affects about 3 million Americans.
Georgia Tech engineers and Emory University clinicians have successfully engrafted insulin-producing cells into a diabetic mouse model, reversing diabetic symptoms in the animal in as little as 10 days.
The research team engineered a biomaterial to protect the cluster of insulin-producing cells – donor pancreatic islets – during injection. The material also contains proteins to foster blood vessel formation that allow the cells to successfully graft, survive and function within the body.
“It’s very promising,” said Andrés Garcia, Georgia Tech professor of mechanical engineering. “There is a lot of excitement because not only can we get the islets to survive and function, but we can also cure diabetes with fewer islets than are normally needed.”
The research article – a partnership with Emory’s Dr. Robert Taylor and Dr. Peter Thule that was funded in part by theJDRF, the leading global organization funding Type 1 diabetes research – will be published in the June issue of the journal Biomaterials.
Organizations such as JDRF are dedicated to finding a cure for Type 1 diabetes, a chronic disease that occurs when the pancreas produces little or no insulin, a hormone that allows the transport of sugar and other nutrients into tissues where they are converted to energy needed for daily life.
Pancreatic islet transplantation re-emerged as a promising therapy in the late 1990s. Patients with diabetes typically find it difficult to comply with multiple daily insulin injections, which only partially improve long-term outcomes. Successful islet transplantation would remove the need for patients to administer insulin. While islet transplantation trials have had some success, and control of glucose levels is often improved, diabetic symptoms have returned in most patients and they have had to revert to using some insulin.
Unsuccessful transplants can be attributed to several factors, researchers say. The current technique of injecting islets directly into the blood vessels in the liver causes approximately half of the cells to die due to exposure to blood clotting reactions. Also, the islets – metabolically active cells that require significant blood flow – have problems hooking up to blood vessels once in the body and die off over time.
Georgia Tech and Emory researchers engineered a hydrogel, a material compatible with biological tissues that is a promising therapeutic delivery vehicle. This water-swollen, cross-linked polymer surrounds the insulin-producing cells and protects them during injection. The hydrogel containing the islets was delivered to a new injection site on the outside of the small intestine, thus avoiding direct injection into the blood stream.
Once in the body, the hydrogel degrades in a controlled fashion to release a growth factor protein that promotes blood vessel formation and connection of the transplanted islets to these new vessels. In the study, the blood vessels effectively grew into the biomaterial and successfully connected to the insulin-producing cells.
Four weeks after the transplantation, diabetic mice treated with the hydrogel had normal glucose levels, and the delivered islets were alive and vascularized to the same extent as islets in a healthy mouse pancreas. The technique also required fewer islets than previous transplantation attempts, which may allow doctors to treat more patients with limited donor samples. Currently, donor cells from two to three cadavers are needed for one patient.
While the new biomaterial and injection technique is promising, the study used genetically identical mice and therefore did not address immune rejection issues common to human applications. The research team has funding from JDRF to study whether an immune barrier they created will allow the cells to be accepted in genetically different mice models. If successful, the trials could move to larger animals.
“We broke up our strategy into two steps,” said Garcia, a member of Georgia Tech’s Petit Institute for Bioengineering and Bioscience. “We have shown that when delivered in the material we engineered, the islets will survive and graft. Now we must address immune acceptance issues.”
The Latest Bing News on:
Diabetes mellitus type 1
- Troponin and D-dimer significant predictors of pulmonary embolism in T2DM, reveals studyon April 26, 2024 at 9:15 pm
Type 2 diabetes mellitus (T2DM) is a condition characterized by a prothrombotic, proinflammatory, and hypofibrinolytic state. However, the relationship between T2DM and pulmonary embolism ...
- Diabetes Management Program Cuts Dementia Risk in Patients With Type 2 Diabeteson April 26, 2024 at 5:44 am
Researchers explored the association between receiving a multidisciplinary primary care diabetes management program and the subsequent risk for dementia among patients with type 2 diabetes.
- Diabetes: Know Symptoms, Causes, Types And Treatmenton April 26, 2024 at 3:17 am
“Common symptoms of diabetes include feeling very thirsty, urinating a lot, being more tired than usual, losing weight without trying, and having blurry vision. If you notice these signs, see a doctor ...
- Signs and Symptoms of Diabetes Insipiduson April 24, 2024 at 9:30 am
Diabetes insipidus is a rare condition that causes extreme thirst and frequent urination. Headache and double vision are also possible symptoms.
- Study highlights nutrition therapy's potential to manage gestational diabetes effectivelyon April 23, 2024 at 8:22 pm
Study investigates the effects of medical nutrition therapy on gestational diabetes mellitus, emphasizing the beneficial roles of specific dietary patterns and nutrient supplements in managing this ...
- University of Birmingham: New International Medical Code Launched for Presymptomatic Type 1 Diabeteson April 23, 2024 at 4:37 am
Researchers at the University of Birmingham have partnered with NHS England to produce a diagnostic code tailored for individuals in the early phases of type 1 diabetes, enhancing patient prospects fo ...
- The Healing Harmony: Study shows Taichi's positive impact on glycemic control and lung diffusion capacity in type 2 diabeteson April 21, 2024 at 9:30 pm
"Reciprocally, Taichi training reduced inflammatory markers and enhanced endothelial nitric oxide synthase (eNOS), which reinforces with improved glycemic control, contribute to improved pulmonary ...
- Launch of new international medical code for presymptomatic type 1 diabeteson April 17, 2024 at 3:30 am
University of Birmingham and NHS England researchers have created a diagnostic code for presymptomatic type 1 diabetes to enhance healthcare treatment.
- Head-to-Head Study Finds TheracosBio's BRENZAVVY® (bexagliflozin) Non-Inferior to Dapagliflozin in Chinese Patients With Type 2 Diabeteson April 12, 2024 at 5:08 am
BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. The randomized, double-blind, active-controlled trial enrolled 406 patients with type 2 ...
- Maternal diabetes linked to a slight increase in ADHD risk in childrenon April 9, 2024 at 10:31 pm
Large-scale study reveals that maternal diabetes mellitus is associated with a slightly increased risk of ADHD in offspring, highlighting the complex interplay of genetic and environmental factors in ...
The Latest Google Headlines on:
Diabetes mellitus type 1
[google_news title=”” keyword=”Diabetes mellitus type 1″ num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Cure for type 1 diabetes
- Diabetes: Know Symptoms, Causes, Types And Treatmenton April 26, 2024 at 3:17 am
“Common symptoms of diabetes include feeling very thirsty, urinating a lot, being more tired than usual, losing weight without trying, and having blurry vision. If you notice these signs, see a doctor ...
- Breakthrough: Rare Gene Mutation Offers Clues to Preventing Type 1 Diabeteson April 25, 2024 at 8:39 pm
A unique genetic mutation in two siblings – that has never been seen in anyone else – has been discovered by UK researchers at the University of Exeter, pointing the way towards new treatment options ...
- CGM Use Amplifies GLP-1 Therapy in Type 2 Diabeteson April 25, 2024 at 5:48 am
Researchers conducted a real-world study to compare the effectiveness of GLP-1 therapy plus CGM and GLP-1 therapy alone among adults with type 2 diabetes.
- Advanced insulin pumps enhance blood sugar management in type 1 diabeteson April 24, 2024 at 9:48 pm
Blood sugar levels improve when adults with type 1 diabetes use modern insulin pumps. These are the findings of a study conducted at the University of Gothenburg.
- Huddle for Diabetes event provides advice, screenings on eve of the NFL Drafton April 24, 2024 at 8:18 pm
ROYAL OAK, Mich. (WXYZ) — Emagine Royal Oak hosted a Huddle for Diabetes event on the eve of the NFL Draft. NFL Alumni Health and Beyond Type 1 organized the community wellness event that took place ...
- Type 1 on a GLP-1 Drug? Watch for Hypoglycemia and DKAon April 22, 2024 at 7:05 pm
Explore GLP-1 agonists for weight loss in type 1 diabetes with caution. Understand potential risks like hypoglycemia and DKA, while balancing benefits for heart and kidney health.
- Siblings with unique gene mutation offer insights into type 1 diabetes treatmenton April 20, 2024 at 10:51 pm
Two siblings who have the only known mutations in a key gene anywhere in the world have helped scientists gain new insights that could help progress the search for new treatments in type 1 diabetes.
- American College Of Physicians Officially Recommends GLP-1s Like Ozempic For Diabetes Treatment—Despite Shortage Concernson April 19, 2024 at 10:10 am
The body for the first time is calling for GLP-1s as a treatment for Type 2 diabetes, but the medications are in short supply.
- GLP-1 drugs for diabetes and weight loss unlikely to affect thyroid cancer riskon April 15, 2024 at 8:30 am
New research from Sweden has found that GLP-1 agonist drugs used to treat diabetes and obesity are unlikely to increase thyroid cancer risk, as some previous studies had suggested.
- Preventing type 1 diabetes: UMass Chan researcher developing skin treatment, with potential broader applications to prevent diabeteson April 15, 2024 at 4:44 am
Dr. John Harris, professor and chair of the Department of Dermatology at UMass Chan Medical School in Worcester and founding director of the school’s Vitiligo Clinic and Research Center, Harris has ...
The Latest Google Headlines on:
Cure for type 1 diabetes
[google_news title=”” keyword=”cure for type 1 diabetes” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]